Evidence map›Paper›PMID 40290436›Full record

ArticleFrontiers in pharmacology2025

Ultrasensitive RNase H activity detection using the transcription-based hybrid probe and CRISPR/cas12a signal amplifier.

Sheng Ding, Yinghua Wei, Minglong Yang, Jinyi Shi, Kaiyuan Ren, Xinli Li, Zhuo Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sheng Ding *Clinical Medical College and Affiliated Hospital, Chengdu University, Chengdu, China.
Yinghua Wei *Guangzhou National Laboratory, Guangzhou, China.
Minglong Yang *Clinical Medical College and Affiliated Hospital, Chengdu University, Chengdu, China.
Jinyi ShiNatural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China.
Kaiyuan RenNatural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China.
Xinli LiClinical Medical College and Affiliated Hospital, Chengdu University, Chengdu, China.
Zhuo TangNatural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ribonuclease H (RNase H), a critical functional protein in replication and genome stability, is emerging as a crucial therapeutic target for various diseases, including immune disorders. We present a transcription-based hybrid probe, referred to as Hybprobe, and a CRISPR/Cas12a signal amplifier for the rapid, sensitive, and low-cost detection of RNase H activity. In this method, the RNA strand of the Hybprobe is specifically cleaved by RNase H, releasing a single-stranded DNA activator that facilitates recognition and cleavage by the Cas12a/crRNA complex, triggering signal amplification via Cas12a's trans-cleavage activity. The proposed method demonstrates ultra-high sensitivity, capable of detecting RNase H as low as 9.02 × 10

Indexed as

activity detectionCRISPR/Cas12ahybprobeinhibitor screeningRnase H

Identifiers

PMID40290436
PMCPMC12021801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.